Gå till Affärer
Riskkapital | Konsument- & detaljhandel

John Bell & Croyden has been acquired by Bestway (Holdings) Ltd.

The shareholders of John Bell & Croyden, Aurelius, have sold the business to Bestway Group.

John Bell & Croyden is an operator of a high-end pharmacy in central London.

Bestway Group is a diversified multinational family-owned business with annualized turnover in excess of US$5.7 billion.

Aurelius is a globally active alternative investor focused on private equity, private debt and real estate.

Oaklins Cavendish, based in the UK, advised the shareholders of John Bell & Croyden on the sale of the business to Bestway Group.

Prata med transaktionsteamet

Henry Wells

Partner
London, Storbritannien
Oaklins Cavendish

Lord Leigh of Hurley

Principal
London, Storbritannien
Oaklins Cavendish

Leo Holdsworth

Senior Associate
London, Storbritannien
Oaklins Cavendish

Relaterade affärer

OBI Group has acquired the OBI and individual DIG stores from Migros
Konsument- & detaljhandel

OBI Group has acquired the OBI and individual DIG stores from Migros

As part of a strategic review, Migros has decided to divest its DIY business, which included several “Do It + Garden” and “OBI” locations. Migros had operated the Swiss OBI stores as a franchisee. In OBI Group Holding, Migros has found the ideal partner to ensure continuity for both its customers and employees.

Lär dig mer
Den Berk Délice accelerates growth through strategic partnership
Riskkapital | Jordbruk

Den Berk Délice accelerates growth through strategic partnership

Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.

Lär dig mer
Xiel Limited has been acquired by MIS Healthcare
Riskkapital | Hälsovård

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Lär dig mer